Journal
BRITISH JOURNAL OF PSYCHIATRY
Volume 190, Issue -, Pages 531-532Publisher
ROYAL COLLEGE OF PSYCHIATRISTS
DOI: 10.1192/bjp.bp.106.031393
Keywords
-
Categories
Funding
- Medical Research Council [G9102334, MC_U951162643] Funding Source: Medline
- Medical Research Council [G9102334, MC_U951162643] Funding Source: researchfish
- MRC [MC_U951162643, G9102334] Funding Source: UKRI
Ask authors/readers for more resources
We used functional magnetic resonance imaging to investigate the effects of short-term treatment with reboxetine, a selective noradrenaline reuptake inhibitor, on emotional facial processing in healthy volunteers. Reboxetine was associated with a reduced amygdala response to fearful faces and increased activation to happy v. neutral facial expressions in the right fusiform gyrus, relative to placebo treatment and in the absence of changes in mood. Our results show that reboxetine modulates the neural substrates of emotional processing, highlighting a mechanism by which drug treatment could normalise negative bias in depression and anxiety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available